# Feasibility Assessment: Neurodegeneration Therapeutic Hypotheses
## Executive Summary
| Hypothesis | Primary Modality | Feasibility Tier | Timeline | Cost Range |
|------------|------------------|------------------|----------|------------|
| **7. cGAS-STING/Tau** | STING inhibitors | **Tier 1** | 5-8 yr | $100-200M |
| **2. TREM2/DAM** | Agonist antibodies | **Tier 2** | 6-9 yr | $150-250M |
| **6. Astrocyte/GRN** | MCT4 modulators | **Tier 2** | 7-10 yr | $150-250M |
| **1. TDP-43/Splicing** | ASOs | **Tier 3** | 10-12 yr | $150-300M |
| **3. Lysosome/αSyn** | TRPML1 agonists | **Tier 3** | 10-15 yr | $200-400M |
| **5. N-acetylation** | Enzyme activators | **Tier 4** | 12-15 yr | $300M+ |
| **4. circHomer1a** | Gene therapy | **Tier 5** | 15+ yr | $300M+ |
---
## Hypothesis 7: cGAS-STING Pathway in Tau Propagation
**Revised Confidence: 0.76** | **Feasibility Tier: 1**
### Druggability — HIGH
STING is one of the most actively drugged targets in neurodegeneration currently. Multiple BBB-penetrant small-molecule STING inhibitors are in active development (HTT-SAM? no—STING inhibitors such as C-176, H-151, and newer optimized analogs show CNS exposure). cGAS inhibitors are earlier but structurally tractable. Downstream readouts (IFN-β, IRF3 phosphorylation, CXCL10) are quantifiable via CSF cytokines and provide pharmacodynamic markers. **Druggability score: 7/10**
### Biomarkers — GOOD
The pathway generates measurable, clinically actionable biomarkers:
- **CSF cytokines**: IP-10, IFN-β, and inflammatory panels elevated in AD/tauopathy brains provide target engagement readouts
- **Neuroinflammatory PET**: [¹¹C]-PK11195 and newer TSPO ligands measure microglial activation; newer-generation translocator protein tracers offer improved signal-to-noise
- **Patient selection**: No single biomarker definitively enriches for cGAS-STING hyperactivation, but inflammatory CSF profiles combined with Braak stage may stratify candidates
- **Gap**: No validated companion diagnostic; reliance on indirect neuroinflammatory markers
### Model Systems — ROBUST
- P301S tauopathy mice are well-characterized with established readouts
- Human post-mortem tissue shows Type I interferon response signatures across AD and Pick's disease
- iPSC-derived neurons and microglia allow human mechanistic studies
- **Limitation**: Mouse CNS immune architecture differs from human; microglial density and responses are not fully conserved
### Clinical Development Constraints — MODERATE
- **Regulatory pathway**: Reasonable precedent—anti-inflammatory approaches in neurodegeneration have regulatory frameworks; FDA/NDA pathway for CNS immunomodulation exists
- **Patient selection**: Requires stratification beyond clinical diagnosis; inflammatory "hot" vs. "cold" tauopathy may have different treatment responses
- **Comparator arm design**: Ethical—standard of care (acetylcholinesterase inhibitors) may confound results
- **Primary endpoint**: Cognitive measures are established but insensitive; composite cognitive-motor endpoints preferred
### Safety — MANAGEABLE
- **Peripheral immunity risk**: STING is widely expressed; chronic systemic STING inhibition may impair innate antiviral responses
- **BBB-penetrant inhibitor margin**: Preclinical data suggest adequate safety windows, but chronic CNS immunomodulation risks infection susceptibility and autoimmune-like effects
- **Mouse data**: STING knockout and inhibitor-treated mice show increased susceptibility to viral infections but generally tolerated otherwise
- **Monitoring required**: Peripheral cytokine panels, infection surveillance, and regular neurologic assessment
### Timeline/Cost Realism — 5-8 years to Phase II, $100-200M
Multiple STING inhibitor programs exist, reducing de-risking burden. Phase I could initiate within 3-4 years if a BBB-penetrant lead compound advances. **This is the most translationally mature hypothesis in the set.**
---
## Hypothesis 2: TREM2-Dependent Microglial State Transition
**Revised Confidence: 0.61** | **Feasibility Tier: 2**
### Druggability — MODERATE-HIGH
Antibody therapeutics against TREM2 are actively in development (AL002c/Alector, PRJ-3070/Prevail). The target is well-validated extracellular with clear structure-activity relationships. However:
- **BBB penetration**: Monoclonal antibodies require active transport mechanisms or BBB-shuttle technologies—currently a significant limitation
- **Target engagement marker**: Soluble TREM2 (sTREM2) in CSF is measurable and serves as a pharmacodynamic readout
- **Downstream SYK pathway**: More challenging to drug selectively; SYK inhibitors are in oncology but carry toxicity concerns
- **Druggability score: 6/10**
### Biomarkers — MODERATE
- **sTREM2 in CSF**: Acceptable pharmacodynamic marker for target engagement
- **Neuroinflammatory PET**: Microglial activation imaging can serve as downstream readout
- **DAM signature transcripts**: Single-cell RNA-seq from blood or CSF cells can track transcriptomic states (research use only currently)
- **Patient selection**: TREM2 variant carriers represent obvious enriched population; however, R47H/R62H carriers are only a subset of AD patients
- **Gap**: No validated DAM-state biomarker for routine clinical use; snRNA-seq remains research-grade
### Model Systems — ADEQUATE WITH CAVEATS
- **